Stoke Therapeutics, Inc. (STOK) — 10-Q Filings
All 10-Q filings from Stoke Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Stoke Swings to Profit on Revenue Surge, Q3 Loss Widens
— Nov 4, 2025 Risk: high
Stoke Therapeutics, Inc. reported a significant increase in revenue for the nine months ended September 30, 2025, reaching $183.0 million, a substantial rise fr -
Stoke's Q2 Losses Widen Amid Increased R&D Spend
— Aug 12, 2025 Risk: high
Stoke Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The net loss for the th -
Stoke Therapeutics Files Q1 2025 10-Q
— May 13, 2025 Risk: medium
Stoke Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly ASOthera Pharmaceuticals, Inc., is involved in pharmaceutica -
Stoke Therapeutics Q3 2024 Financial Update
— Nov 5, 2024 Risk: medium
Stoke Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results, including details on its equity an -
Stoke Therapeutics Files Q2 2024 10-Q
— Aug 7, 2024 Risk: medium
Stoke Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business ope -
Stoke Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 6, 2024 Risk: low
Stoke Therapeutics, Inc. (STOK) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Stoke Therapeutics, Inc. filed a 10-Q report for the period ending
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX